The company said the results from the evoke study, which tested an oral semaglutide pill for early-stage symptomatic Alzheimer's disease, were "not what we had hoped for"
The pair have entered into a multi-year strategic agreement to accelerate drug development timelines, strengthen US manufacturing capabilities and help bring lifesaving...
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.